Literature DB >> 15451461

Side-by-side comparison of lentivirally transduced and mRNA-electroporated dendritic cells: implications for cancer immunotherapy protocols.

Melissa Dullaers1, Karine Breckpot, Sonja Van Meirvenne, Aude Bonehill, Sandra Tuyaerts, Annelies Michiels, Lieven Straetman, Carlo Heirman, Catherine De Greef, Pierre Van Der Bruggen, Kris Thielemans.   

Abstract

The use of tumor antigen-loaded dendritic cells (DC) is one of the most promising approaches to inducing a tumor-specific immune response. We compared electroporation of mRNA to lentiviral transduction for the delivery of tumor antigens to human monocyte-derived and murine bone marrow-derived DC. Both lentiviral transduction and mRNA electroporation induced eGFP expression in on average 81% of human DC. For murine DC, eGFP mRNA electroporation (62%) proved to be more efficient than lentiviral transduction (47%). When we used tNGFR as a transgene we observed lentiviral pseudotransduction that overestimated lentiviral efficiency. Neither gene transfer method had an adverse effect on viability, phenotype, or allostimulatory capacity of either human or murine DC. Yet, the mRNA-electroporated DC showed a reduced production of IL-12p70 compared to their lentivirally transduced and unmodified counterparts. Human Ii80MAGE-A3-modified DC and murine Ii80tOVA-modified DC were able to present antigenic epitopes in the context of MHC class I and class II. Both types of modified murine DC were able to induce OVA-specific cytotoxic T cells in vivo; however, the mRNA-electroporated DC were less potent. Our data indicate that this may be related to their impaired IL-12 production.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15451461     DOI: 10.1016/j.ymthe.2004.07.017

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  29 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

2.  Tubulovesicular structures within vesicular stomatitis virus G protein-pseudotyped lentiviral vector preparations carry DNA and stimulate antiviral responses via Toll-like receptor 9.

Authors:  Andreas Pichlmair; Sandra S Diebold; Stephen Gschmeissner; Yasuhiro Takeuchi; Yasuhiro Ikeda; Mary K Collins; Caetano Reis e Sousa
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

3.  Programming the next generation of dendritic cells.

Authors:  Richard G Carroll; Carl H June
Journal:  Mol Ther       Date:  2007-05       Impact factor: 11.454

4.  Studies on mRNA electroporation of immature and mature dendritic cells: effects on their immunogenic potential.

Authors:  Ozcan Met; Jens Eriksen; Inge Marie Svane
Journal:  Mol Biotechnol       Date:  2008-06-10       Impact factor: 2.695

Review 5.  Recombinant lentivector as a genetic immunization vehicle for antitumor immunity.

Authors:  Yukai He; David Munn; Louis D Falo
Journal:  Expert Rev Vaccines       Date:  2007-12       Impact factor: 5.217

6.  Antigen-presenting cell-targeted lentiviral vectors do not support the development of productive T-cell effector responses: implications for in vivo targeted vaccine delivery.

Authors:  C Goyvaerts; Y De Vlaeminck; D Escors; S Lienenklaus; M Keyaerts; G Raes; K Breckpot
Journal:  Gene Ther       Date:  2017-05-25       Impact factor: 5.250

7.  A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

Authors:  Rémi J Creusot; Pearl Chang; Don G Healey; Irina Y Tcherepanova; Charles A Nicolette; C Garrison Fathman
Journal:  Mol Ther       Date:  2010-07-13       Impact factor: 11.454

Review 8.  Dendritic cell-based vaccines: barriers and opportunities.

Authors:  Jessica A Cintolo; Jashodeep Datta; Sarah J Mathew; Brian J Czerniecki
Journal:  Future Oncol       Date:  2012-10       Impact factor: 3.404

9.  High-level antigen expression and sustained antigen presentation in dendritic cells nucleofected with wild-type viral mRNA but not DNA.

Authors:  Nada M Melhem; Sherrianne M Gleason; Xiang Dong Liu; Simon M Barratt-Boyes
Journal:  Clin Vaccine Immunol       Date:  2008-07-30

10.  Induction of protective cytotoxic T-cell responses by a B-cell-based cellular vaccine requires stable expression of antigen.

Authors:  S Guo; J Xu; W Denning; Z Hel
Journal:  Gene Ther       Date:  2009-07-30       Impact factor: 5.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.